Using a modified kidney protein to treat kidney injury
Official title: Validation of recombinant truncated Tamm-Horsfall protein as a therapeutic tool for kidney injury
Funded at Rlr VA Medical Center · NIH-10927459 · Data updated 2026-11-12
This study is looking at a special version of a protein that might help people with acute kidney injury by reducing inflammation and helping their kidneys heal, especially for those who don’t have enough of this protein naturally.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rlr VA Medical Center NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| NIH project number | 1I21BX006519-01 |
| Project ID | NIH-10927459 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with acute kidney injury, particularly those with a history of chronic kidney disease or THP deficiency.
✕Less likely to help
Patients with stable kidney function and no history of acute kidney injury are unlikely to benefit from this research.
What this research studies
This research investigates the use of a modified version of Tamm-Horsfall protein (THP) as a potential treatment for acute kidney injury (AKI). The study aims to understand how this protein can help reduce inflammation and promote healing in the kidneys, especially in patients who have a deficiency of THP. By administering this recombinant protein, the researchers hope to improve kidney function and recovery in affected individuals. The approach includes assessing the safety and effectiveness of the treatment through pharmacokinetic studies.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from acute kidney injury.
How similar studies have gone: Previous research has shown promising results with similar therapeutic approaches targeting kidney injury, suggesting potential for success in this study.
Where this research is happening
-
Rlr VA Medical Center
Indianapolis, United States Active
Researchers
- Principal investigator: Ashkar, Tarek Maurice — Rlr VA Medical Center
- Study coordinator: Ashkar, Tarek Maurice
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.